ViiV Healthcare

Name

ViiV Healthcare

Legal name

ViiV Healthcare UK Limited

Website

https://viivhealthcare.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

akta.pro secondary industry

HIV/AIDS Medicine (HLAKAGAB)

Keywords

• HIV pharmaceuticals
• Antiretroviral therapy
• Long-acting injectables
• HIV treatment
• HIV prevention

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. HIV Medicines Sales: ViiV Healthcare generates revenue through the sale of 15 approved HIV medicines including Cabenuva, Dovato, Triumeq, Tivicay, and others. The HIV franchise generated £1,824 million with 10% growth in Q1 2026. Revenue is derived from prescription sales through healthcare systems, pharmacies, and national health programs globally.
2. Licensing and Intellectual Property: Voluntary license agreements allowing generic manufacturers to develop paediatric formulations of medicines where 99% of children living with HIV live, with intellectual property sharing through partnerships like Medicines Patent Pool (MPP).

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

ViiV Healthcare develops, manufactures, and commercializes a portfolio of 15 approved HIV prescription medicines for both treatment and prevention (PrEP). The portfolio spans multiple drug classes including INSTIs (dolutegravir, cabotegravir), NRTIs, NNRTIs, CCR5 antagonists, and attachment inhibitors, delivered as oral daily tablets and long-acting injectables. The company is the only pharmaceutical company 100% dedicated solely to HIV medicines and research.

Product overview

ViiV Healthcare is a global specialist pharmaceutical company solely focused on HIV medicines and research, offering a portfolio of 15 approved prescription medicines spanning multiple drug classes including integrase strand transfer inhibitors (INSTIs), non-nucleoside reverse transcriptase inhibitors, entry inhibitors (CCR5 antagonists, attachment inhibitors), and nucleoside/nucleotide reverse transcriptase inhibitors. The portfolio includes both oral daily treatments (Dovato, Tivicay, Triumeq, Juluca, Rukobia, Selzentry) and long-acting injectable formulations (Cabenuva, Apretude/Vocabria). The company's product strategy centers on 'INSTI at the core' development with a focus on ultra-long-acting options (dosing intervals of four months or longer) combining INSTIs with broadly neutralising antibodies or capsid inhibitors. The pipeline includes investigational candidates like lotivibart (N6LS), VH184, VH499, and cabotegravir ULA targeting treatment and prevention applications.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 94% viral suppression maintained with lotivibart (N6LS) every four months + cabotegravir LA at 12 months
• +5 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered key.

• International AIDS Society (IAS)keyStrategic or Co-development PartnerViiV Healthcare partners with IAS for global health collaboration, working hand-in-hand to increase access to medicines and reach those most impacted by HIV. IAS is a leading independent organization advancing HIV knowledge and policy.
• Clinton Health Access Initiative (CHAI)keyStrategic or Co-development PartnerViiV Healthcare collaborates with CHAI to improve access to HIV medicines in low-and-middle-income countries. CHAI negotiates with governments and manufacturers to make treatments more affordable and available.
• Medicines Patent Pool (MPP)keyStrategic or Co-development PartnerViiV Healthcare shares intellectual property through MPP voluntary licensing agreements, allowing generic manufacturers to develop paediatric formulations of medicines where 99% of children living with HIV live.
• Johnson & JohnsonkeyStrategic or Co-development PartnerJohnson & Johnson provided medications for the LATITUDE phase III trial of long-acting injectable cabotegravir and rilpivirine, collaborating on research for populations with adherence challenges.
• Global FundkeyStrategic or Co-development PartnerGlobal Fund partnership for HIV, TB, and malaria responses with ViiV committing $260 million for catalytic investments including scale-up of HIV prevention tool Lenacapavir, working to prevent 400 million infections.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Others

• GSK: 78.3% parent of ViiV Healthcare and consolidator of the HIV franchise within its specialty medicines segment. Strategic decisions, capital allocation, and global commercial infrastructure for ViiV flow through GSK.
• Mylan (Viatris): Generic manufacturer that has commercialised HIV antiretrovirals globally and competes on price in LMIC markets where ViiV's voluntary-licensed paediatrics overlap. Acts as a payer-friendly generics alternative rather than a direct treatment innovator.

Broad incumbents

• AbbVie: Diversified large-cap pharma with prior HIV asset exposure (Norvir). Not a direct HIV treatment peer today but competes broadly for specialty pharma capital and M&A focus in virology and infectious disease.
• Shionogi & Co: Japanese pharmaceutical company holding 21.7% of ViiV post the 2026 restructuring. Contributes HIV R&D capabilities and Asian market access to the ViiV partnership and runs a broader anti-infective pipeline.
• Bristol-Myers Squibb: Historical HIV player (Atripla, Sustiva, Reyataz) now operating as a broader specialty biopharma. Less concentrated in HIV but retains late-stage assets and an INSTI heritage relevant to ViiV's positioning.

Emerging players

• Theratechnologies: Smaller HIV-focused specialty pharma with Trogarzo (ibalizumab) for heavily treatment-experienced patients. Comparable focus on niche HIV populations and long-acting/biologic HIV modalities.
• TaiMed Biologics: Developer of ibalizumab-uiyk, a CD4-directed HIV entry inhibitor licensed to Theratechnologies. Operates in the same niche HIV treatment-experienced population targeted by ViiV's Rukobia (fostemsavir).

Direct peers

• Gilead Sciences: Global HIV market leader with Biktarvy (bictegravir-based regimen), Descovy, and lenacapavir (Sunlenca). Direct competitor to ViiV across both treatment and prevention, with comparable INSTI-centred pipeline and broader commercial scale.
• Merck & Co (MSD): HIV franchise via Delstrigo and Pifeltro (doravirine) competes head-to-head with ViiV's oral combination regimens. Comparable large-pharma HIV offering in treatment-naive and switch populations.
• Johnson & Johnson: Co-developer of rilpivirine (Edurant) and partner providing medication for ViiV's Cabenuva LATITUDE trial. Directly competes in long-acting injectable HIV treatment and has its own HIV prevention pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ViiVUS
• YouTubeyoutube.com/user/viivhealthcare
• Facebookfacebook.com/ViiVHealthcare
• LinkedInlinkedin.com/company/612511
• Instagraminstagram.com/viivhealthcare
• TikToktiktok.com/@viivhealthcare

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ViiV Healthcare